Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy.

Détails

ID Serval
serval:BIB_2AF37A51F489
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy.
Périodique
Journal of Clinical Virology
Auteur(s)
Emery V.C., Manuel O., Asberg A., Pang X., Kumar D., Hartmann A., Preiksaitis J.K., Pescovitz M.D., Rollag H., Jardine A.G., Gahlemann C.G., Humar A.
ISSN
1873-5967 (Electronic)
ISSN-L
1386-6532
Statut éditorial
Publié
Date de publication
2012
Volume
54
Numéro
1
Pages
56-60
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
BACKGROUND: The impact of different cytomegalovirus (HCMV) glycoprotein B (gB) genotypes on pathogenesis remains controversial.
OBJECTIVES: To investigate the effect of gB genotypes either as single infections or as part of multiple infections on the early kinetics of response to ganciclovir therapy.
METHODS: Patients (n=239) enrolled in a study of intravenous ganciclovir or valganciclovir for the treatment of HCMV disease were analysed by a gB genotype specific PCR to quantify the amount of each gB genotype present at initiation of therapy (baseline, day 0) and at days 3, 7, 14 and 21 post therapy.
RESULTS AND CONCLUSIONS: In all gB groups (individual gB genotype infections and mixed genotype infections) there was a biphasic decline in viral load after therapy. The first phase half life (days 0-3) was ≤1 day and was followed over the next 18 days by a slower second phase decline with half lives ranging from 3.4 to 4.4 days. The 1st phase rapid decline in viral load was dependent upon gB genotype whereas the ultimate viral load reduction at day 21 was relatively insensitive to gB genotype. A strong correlation between 1st phase decline and extent of viral load reduction at day 21 was observed (r=0.37; p=0.002). These data imply that early reductions in HCMV load after therapy may be useful in predicting the duration of drug therapy needed to control HCMV replication.
Mots-clé
Antiviral Agents/administration & dosage, Cytomegalovirus/genetics, Cytomegalovirus/isolation & purification, Cytomegalovirus Infections/drug therapy, Cytomegalovirus Infections/virology, DNA, Viral/genetics, Ganciclovir/administration & dosage, Ganciclovir/analogs & derivatives, Genotype, Humans, Infusions, Intravenous, Polymerase Chain Reaction, Time Factors, Treatment Outcome, Viral Envelope Proteins/genetics, Viral Load
Pubmed
Web of science
Open Access
Oui
Création de la notice
23/03/2012 15:07
Dernière modification de la notice
20/08/2019 13:10
Données d'usage